Marwah Medicine

INICET, Medical, Medicine, Medicine classes, NExT, NExT Exam

FDA Approves First Oral Drug for Dermatomyositis

Brepocitinib (Lisraya) Explained: Mechanism, VALOR Trial, Dose, Safety & Exam Pearls By Dr Deepak Marwah  |  Marwah Medicine A major change has arrived in dermatomyositis treatment. On August 27, 2026, the US FDA approved brepocitinib (Lisraya) tablets for adults with dermatomyositis, making it the first FDA-approved oral treatment specifically indicated for adult dermatomyositis. HIGH-YIELD ONE-LINER Brepocitinib = oral selective TYK2-JAK1 inhibitor → adult dermatomyositis. For medical students, that one line may be enough to answer a future NEET-PG, INI-CET or FMGE update question. For clinicians, however, the story is more interesting: the Phase 3 VALOR trial showed meaningful improvement in overall dermatomyositis activity, skin disease, physical function and glucocorticoid tapering with the 30-mg dose. Why this approval matters Dermatomyositis is a systemic autoimmune inflammatory myopathy. The classic teaching focuses on proximal muscle weakness, heliotrope rash and Gottron papules, but clinically the disease may involve skin, muscle, joints, lungs and other organs. Treatment has traditionally relied heavily on glucocorticoids and other immunomodulatory therapies, many used off-label. A specifically approved oral targeted therapy therefore represents an important change in the treatment landscape. What exactly is brepocitinib? Brepocitinib is an oral selective inhibitor of TYK2 and JAK1. These kinases participate in intracellular cytokine signaling pathways involved in immune activation and inflammation. Think of the pathway as: Cytokine signal → JAK/TYK signaling → inflammatory gene signaling → immune-mediated tissue injury. By inhibiting TYK2 and JAK1, brepocitinib modifies several inflammatory signaling pathways implicated in dermatomyositis. The study behind the approval: VALOR The pivotal evidence came from the Phase 3 VALOR trial, a double-blind randomized placebo-controlled study involving 241 adults with dermatomyositis. Participants received brepocitinib 30 mg once daily, brepocitinib 15 mg once daily, or placebo for 52 weeks. Background standard therapies were continued and glucocorticoids were tapered. What did the trial show? Group Mean Total Improvement Score at Week 52 Brepocitinib 30 mg 46.5 Brepocitinib 15 mg 37.5 Placebo 31.2 The 30-mg dose was significantly superior to placebo for the primary endpoint. Importantly, brepocitinib 30 mg was also superior across all nine key secondary endpoints, including skin disease activity, systemic glucocorticoid tapering and functional disability. Improvements in some outcomes were observed as early as week 4. It was not just about muscle enzymes One of the clinically attractive aspects of the VALOR results is that benefit was not restricted to a laboratory value. Dermatomyositis can produce persistent and troublesome cutaneous disease even when muscle manifestations are less dramatic. The 30-mg dose demonstrated improvement across clinically relevant domains including skin activity and physical function. The steroid-sparing angle Long-term glucocorticoid exposure carries substantial toxicity, including diabetes, osteoporosis, infection risk, cataracts, hypertension and weight gain. In VALOR, improvement with brepocitinib 30 mg was accompanied by greater glucocorticoid tapering. This makes the result clinically more meaningful than a change in a single disease marker. Does this replace steroids? No. The approval should not be interpreted as meaning that every newly diagnosed patient can simply replace conventional therapy with one tablet. Dermatomyositis is heterogeneous. Treatment decisions still depend on the severity and pattern of muscle disease, dysphagia, respiratory involvement, interstitial lung disease, skin disease, autoantibody profile, malignancy evaluation, previous treatment response and patient-specific risks. Also remember an important trial detail: standard therapies were continued while glucocorticoids were tapered. Brepocitinib adds a new targeted option; it does not erase the need for individualized specialist management. Dose: the number worth remembering The FDA-approved Lisraya tablet contains brepocitinib 30 mg, administered orally once daily for adults with dermatomyositis. Safety: oral does not mean casual Brepocitinib is a potent immunomodulatory therapy. In VALOR, serious infections occurred more frequently with brepocitinib 30 mg than with placebo (10% versus 1%). The FDA prescribing information contains important warnings and precautions, including serious infections, malignancy, major adverse cardiovascular events and thrombosis. Common adverse reactions reported in the FDA medication information include upper respiratory tract infections, headache, fatigue, urinary tract infection, nausea, bronchitis, arthralgia, diarrhea, back pain, falls, influenza and acne. Clinical message: “Oral” should never be confused with “low-risk.” Appropriate patient selection, screening and monitoring remain essential. What should medical students remember? Drug: Brepocitinib Trade name: Lisraya Route: Oral, once daily Dose: 30 mg once daily Mechanism: Selective TYK2-JAK1 inhibitor Indication: Dermatomyositis in adults FDA approval: August 27, 2026 Key trial: VALOR Potential exam question A patient with dermatomyositis is started on a newly FDA-approved oral therapy that selectively inhibits TYK2 and JAK1. Which drug is most likely being prescribed? Answer: Brepocitinib (Lisraya). The bigger lesson: targeted therapy is entering myositis For years, dermatomyositis was taught through its memorable clinical signs: heliotrope rash, Gottron papules and proximal muscle weakness. Those remain fundamental. But modern medicine increasingly asks a second question: which molecular pathways are driving the disease, and can those pathways be targeted? Brepocitinib represents that transition from broad immunosuppression toward more targeted immune modulation. Its ultimate place in treatment algorithms will continue to evolve with real-world experience, longer-term safety data, accessibility and cost. But the 2026 approval itself is already an important milestone in dermatomyositis therapy. Frequently Asked Questions What is the new oral drug for dermatomyositis? Brepocitinib, marketed as Lisraya, was FDA-approved in August 2026 for the treatment of dermatomyositis in adults. What is the mechanism of brepocitinib? Brepocitinib is an oral selective inhibitor of TYK2 and JAK1, modifying cytokine signaling involved in inflammatory and autoimmune pathways. What is the dose of brepocitinib for dermatomyositis? The FDA-approved Lisraya dose is 30 mg orally once daily. Is brepocitinib a JAK inhibitor? Yes. Brepocitinib selectively inhibits TYK2 and JAK1. Is brepocitinib better than steroids for dermatomyositis? The treatments should not be reduced to a simple either-or comparison. In VALOR, background standard therapies were continued while glucocorticoids were tapered. The 30-mg brepocitinib group showed clinical benefit and greater glucocorticoid tapering. What is the most important safety concern? Serious infection risk is important. The FDA label also contains warnings and precautions regarding malignancy, major adverse cardiovascular events and thrombosis. What should NEET-PG and INI-CET students remember? Brepocitinib → oral TYK2-JAK1 inhibitor → adult dermatomyositis. Remember the 30-mg once-daily dose […]

Medicine, NEET PG, NExT, NExT Exam

Benefits of joining Dr Marwah Test Series Offline

#drmarwahtestseries #drmarwah #marwahtestseries #fmgcoachingindelhi #fmgexam #next Have you done FMG coaching and used all apps and still the result is not optimum? Did you study 12 hours daily and still did not get optimal results? The real problem is lack of MCQ practice and face to face classes by Dr marwah Test series that will help you fine tune your knowledge and learn to answer questions like a pro. The below are 5 main reasons why you must join this course: Questions of same difficulty level like actual exam. Test series are usually designed to align with the syllabus and pattern of specific exams. Joining one can help you practice and familiarize  yourself with the exam format. Identifying Weaknesses: Regular tests can help identify your strengths and weaknesses in different topics. This allows you to focus your efforts on areas where improvement is needed. We are all weak in some subjects and strong in others. Our structured course provides you ample time to tackle the weak subjects like a pro. Time Management: Practicing with timed tests helps improve your time management skills during the actual exam, ensuring you can complete all sections within the allocated time. Real Exam Simulation: Test series often simulate the actual exam environment, helping you become comfortable with the exam conditions, reducing anxiety, and improving your performance on the actual exam day. Joining a reputed test series can give you a competitive edge by exposing you to a diverse range of questions and scenarios, better preparing you for the challenges of the actual exam.  Structured Learning: Test series are usually structured, covering the entire syllabus in a systematic manner. This ensures that you cover all topics and don't miss any crucial areas during your preparation. our detailed discussion of the entire subject will provide detailed feedback and performance analysis, helping you understand your mistakes and providing insights on how to improve.

Medicine, NEET PG, NExT, NExT Exam

Atrial Fibrillation

2min read #NEETPG #INICET #FMG #FMGMCIEXAM #MEDICINEVIDEOLECTURES #RAPIDREVISIONMEDICINE #NEETSS Notice the irregular RR interval with absence of P waves which is characteristic feature of Atrial fibrillation. You can differentiate from multifocal atrial tachycardia which has >3 morphology of P waves present. Common causes of Atrial fibrillation: ABCD- OT Age: 60 years old Blood Pressure high /Hypertension Cardiac conditions: Coronary artery disease, Cardiac valve disorders, congenital heart defects COPD Diabetes: Individuals with diabetes have an elevated risk of developing AFib. Dilated Cardiomyopathy due to long term alcohol intake leading to Holiday heart syndrome Obstructive sleep apnea Thyroid disease   Clinical features of Atrial fibrillation Irregular Heartbeat: The hallmark of AFib is an irregular and often rapid heartbeat. The pulse may feel chaotic and irregular when palpating the wrist. Palpitations: Some individuals with AFib may feel palpitations, which are sensations of rapid, fluttering, or pounding heartbeats. Fatigue: AFib can lead to reduced cardiac output, causing fatigue and a sense of low energy. Shortness of Breath: Pooling of blood in lungs due to Inability of the heart to pump blood effectively can result in shortness of breath, especially during physical activity. Dizziness or Lightheadedness: Inadequate blood flow to the brain due to irregular heartbeats can cause dizziness or lightheadedness. Chest Pain or Discomfort While chest pain is not as common in AFib as it is in some other heart conditions, some individuals may experience chest discomfort. Syncope (Fainting): In severe cases, AFib can lead to a drop in blood pressure, causing fainting or loss of consciousness. Increased Risk of Stroke: A.Fib is associated with an increased risk of blood clot formation in the atria, which can travel to the brain and cause a stroke. Some individuals may not have noticeable symptoms but are at risk of stroke. Creating a mnemonic can be a helpful memory aid for remembering the treatment of atrial fibrillation. Here’s a mnemonic for the general principles of AFib treatment: Management of Atrial fibrillation: RACE (Remembering “RACE” can help you recall the key components of atrial fibrillation treatment) Rate Control: Use medications to control the heart rate, preventing it from becoming too fast. Common medications include beta-blockers, calcium channel blockers, and sometimes digoxin. Anticoagulation: Reduce the risk of blood clots and stroke by prescribing anticoagulant medications. Common options include warfarin, dabigatran, rivaroxaban, apixaban. For Rheumatic heart disease leading to MS and then atrial fibrillation warfarin is preferred. For Non valvular atrial fibrillation, NOAC are preferred. Chemical Cardioversion: Convert the irregular rhythm back to a normal sinus rhythm. This can be achieved through electrical cardioversion (shocks) or pharmacological cardioversion using medications like amiodarone. Electrical cardioversion: Synchronized DC shock Evaluate and Treat Underlying Causes: Identify and manage any underlying conditions contributing to atrial fibrillation, such as hypertension, heart valve disorders, or thyroid problems

Medicine, NEET PG, NExT, NExT Exam

Broken heart syndrome/ Takotsubo Cardiomyopathy/ Apical Ballooning syndrome

2 min read #NEETPG #INICET #FMGE #DRMARWAHLIVE Broken heart syndrome, also known as stress-induced cardiomyopathy or Takotsubo cardiomyopathy, is a condition where intense emotional or physical stress can cause sudden and severe heart muscle weakness or dysfunction. This condition can mimic a heart attack with symptoms such as chest pain, shortness of breath, and irregular heartbeats, but it’s not caused by blocked arteries typical of a heart attack. Happy Valentine day and be selective about who you date while you keep reading Pathophysiology: It is believed that a surge of stress hormones, such as adrenaline, may temporarily damage the heart muscle, leading to the characteristic symptoms.   Here are some key points about broken heart syndrome: Triggering Factors: Broken heart syndrome can be triggered by various emotional or physical stressors, such as the death of a loved one, a breakup, financial loss, a serious medical diagnosis, or even a surprise party. Symptoms: The symptoms of broken heart syndrome can resemble those of a Myocardial infarction and may include chest pain, shortness of breath, arrhythmias, and in some cases, fainting. Diagnostic Work up: ECG will show ST Elevation Troponin I will be Elevated Echo will show Apical Ballooning Image Coronary angiography will be normal and not show any coronary artery occlusion by any thrombus as it does in STEMI. Therefore, it is a diagnosis of exclusion. Always Rule out Myocarditis and Pheochromocytoma Treatment: Treatment for broken heart syndrome usually involves supportive care to stabilize the patient and manage features of Acute CHF. Intra-aortic balloon pump is preferred over inotropes in cardiogenic shock for broken heart syndrome. Other medications to reduce the workload on the heart, such as beta-blockers, ACE inhibitors are used along with diuretics to relieve pulmonary edema. Most patients recover within a few weeks to months with appropriate medical management. Prognosis: The prognosis for broken heart syndrome is generally favorable, with most patients recovering completely without long-term complications. However, in some cases, there can be complications such as heart failure, arrhythmias, or in rare cases, death.

NEET PG, NExT Exam

Dangal Actor Suhani Bhatnagar 19 years expired due to possible complications of Dermatomyositis on 17 Feb 2024 as per NDTV

2min read #NEETPG #INICET #NEXTEXAM #FMGEXAM Unfortunately, it could be diagnosed very late and caused this irreparable trauma to the Bhatnagar family.  Our condolences to the family. The young actress played role of young Babita Phogat in movie Dangal. Here is a quick revision of Contributors of mortality in Dermatomyositis for medical professionals. Some of the key contributors to mortality in dermatomyositis include: Aspiration Pneumonia: Dysphagia is common in dermatomyositis due to involvement of the muscles involved in swallowing. This can lead to aspiration pneumonia, a serious complication where food, liquids, or saliva are inhaled into the lungs, causing infection and respiratory compromise. Interstitial Lung Disease is a common complication of dermatomyositis, characterized by inflammation and scarring of the lung tissue. Severe ILD can lead to progressive respiratory failure and respiratory complications, which can be fatal. Malignancy: Patients with dermatomyositis have an increased risk of developing certain cancers, particularly ovarian, lung, pancreatic, and gastrointestinal cancers. The presence of malignancy can significantly impact prognosis and contribute to mortality. Cardiac Involvement: While less common than lung involvement, cardiac manifestations such as myocarditis and arrhythmias can occur in dermatomyositis, contributing to mortality, particularly in cases of severe cardiac dysfunction. Infections: Immunosuppressive therapy used to treat dermatomyositis can increase the risk of infections. Patients may be more susceptible to opportunistic infections, which can become serious or life-threatening, especially if not promptly recognized and treated. Complications of Corticosteroid Therapy: Long-term use of high-dose corticosteroids, which are often necessary to control inflammation in dermatomyositis, can lead to complications such as osteoporosis, diabetes, hypertension, and susceptibility to infections, contributing to mortality over time.  

Medicine, Medicine classes, NEET PG, NExT, NExT Exam

HYPERSENSITIVITY PNEUMONITIS

#NEETPG #INICET #FMG #MCISCREENING #MARWAHMEDICINE #PREPLADDERMEDICINE Here is a Quick mnemonic to remember the features of Hypersensitivity pneumonitis is: FARMER’S LUNG 4 F – Fever and Breathing problems A – Acute onset on exposure to grain, Moldy hay and Silage which harbor Thermophilic Actinomycetes R – Respiratory symptoms (cough, dyspnea and Clubbing is seen too M – Malaise starting within 4 to 8 hours of antigenic exposure E – Elevated erythrocyte sedimentation rate and BAL shows lymphocytosis R – Radiographic findings (ground-glass opacities, reticulonodular infiltrates) S – Symptoms improve with removal from exposure L – Lymphocytic alveolitis U – Uncommon but can progress to chronic disease N – Noncaseating granulomas G – Granulomatous inflammation and Diagnosis is based on Clinical prediction rule 4- Type 4 hypersensitivity reaction This mnemonic can help you recall the key features associated with Hypersensitivity pneumonitis.

Medicine, Medicine classes, NEET PG, NExT, NExT Exam

Churg-Strauss syndrome or Eosinophilic Granulomatosis with Polyangiitis

#NEETPG #INICET #FMG #MCISCREENING #MARWAHMEDICINE #PREPLADDERMEDICINE Churg-Strauss syndrome, also known as eosinophilic granulomatosis with polyangiitis (EGPA), has peripheral eosinophilia and pulmonary eosinophilia with infiltrates on CXR. The characteristic feature of this disease is Eosinophilic vasculitis which is not seen in other diseases of lungs which have eosinophilia. A mnemonic to remember Churg-Strauss syndrome is: “CHARM”: C –Cardiac manifestation of myocarditis H –High eosinophil count with as much 75% of TLC being eosinophils A – Asthma and Allergic rhinitis history R – Renal involvement with Glomerulonephritis and Rashes with Purpura M – Mononeuritis multiplex (peripheral neuropathy) Usually, the patient will start having features of asthma and allergic rhinitis by 20-30 years of age. Lateral Peripheral eosinophilia is seen with as much as 75% of TLC being eosinophils. Eosinophils then infiltrate tissues producing neuropathy, myocarditis, eosinophilic gastroenteritis. In late forties or fifties these patients will develop fever, weight loss and malaise with myalgia.   Laboratory Findings Eosinophilia: Elevated eosinophil count in peripheral blood. Elevated Acute Phase Reactants: Such as erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Positive ANCA (Antineutrophil Cytoplasmic Antibodies): Although not always present, ANCA positivity, particularly perinuclear ANCA (p-ANCA), can be seen in a subset of patients. Chest X-ray: May reveal pulmonary infiltrates, nodules, or cavities CT Scan: High-resolution CT may show ground-glass opacities, interstitial fibrosis, or other pulmonary abnormalities. Biopsy Findings: Histopathological examination of affected tissues may reveal eosinophilic infiltration, vasculitis, and granulomatous inflammation. Telegram link: https://t.me/realmarwahmedicine

Medicine, Medicine classes, NEET PG, NExT, NExT Exam

Allergic bronchopulmonary Aspergilloma

#NEETPG #INICET #FMG #MCISCREENING #MARWAHMEDICINE #PREPLADDERMEDICINE 2 min read Telegram link: https://t.me/realmarwahmedicine  Mnemonic to remember the key features of Allergic Bronchopulmonary Aspergillosis (ABPA): “SPADE.” S: Serum Ig E elevation > 1000 IU/ml  is a  hallmark feature of ABPA due to allergic sensitization to Aspergillus. Alternatively Skin test reactivity can be used for diagnosis confirmation. P: Pulmonary findings like infiltrates on CXR and CT scan shows Central Bronchiectasis and Positive Precipitins to aspergillus A: Asthma association though in some cases patient may has cystic fibrosis. Aspergillus colonization of airways is responsible for this presentation. D: Dyspnea: Dyspnea, or shortness of breath, is a common symptom of ABPA, often accompanied by coughing, wheezing, and sputum production. E: Eosinophilia For management of ABPA, itraconazole and systemic steroids are used. Alternatively, Omalizumab is used. The rationale for using itraconazole is to reduce antigenic stimulation.   Comparison of ABPA versus Acute eosinophilic pneumonia   ABPA Allergic interstitial pneumonitis Etiology Allergic reaction to the fungus Aspergillus Unknown, smoking initiation, Vaping Clinical Presentation Brown sputum plugs in an asthmatic or cystic fibrosis Acute respiratory distress, fever, cough, and shortness of breath. The onset is rapid, often within a few days. Chest X-rays may show diffuse infiltrates.   Labs Elevated serum IgE levels, eosinophilia, and positive Aspergillus-specific IgE and IgG antibodies Eosinophilia and BAL showing eosinophils Treatment Steroids plus antifungals Steroids  

Medicine, Medicine classes, NEET PG, NExT, NExT Exam

Revised Mayo Criteria for TTCM

#NEETSS #CARDIOLOGY #MEDICINELECTURES 2 min read The revised Mayo Clinic criteria for Takotsubo cardiomyopathy were developed to improve the accuracy of diagnosing this condition. These criteria were proposed by Mayo Clinic researchers and have been widely adopted in clinical practice. The revised Mayo Clinic criteria for TTCM include:   Transient Hypokinesis, Akinesis, or Dyskinesis of the Left Ventricular Mid-Segments with or without Apical Involvement: Echocardiography or other imaging modalities should demonstrate transient wall motion abnormalities in the left ventricle, typically involving the mid-segments with or without apical involvement. The characteristic appearance is akin to a Japanese octopus trap (Takotsubo). Absence of Obstructive Coronary Artery Disease or Angiographic Evidence of Acute Plaque Rupture: Coronary angiography should reveal no significant obstructive coronary artery disease or evidence of acute plaque rupture that would explain the extent of myocardial dysfunction observed. New ECG Changes (ST-Segment Elevation and/or T-Wave Inversion) or Troponin Elevation: ECG findings may mimic those of acute coronary syndrome, such as ST-segment elevation or T-wave inversion, but without corresponding coronary artery occlusion. Elevated levels of cardiac biomarkers, such as troponin, may also be present, indicating myocardial injury. Absence of Pheochromocytoma and Myocarditis: Other potential causes of acute myocardial dysfunction, such as pheochromocytoma or myocarditis, should be considered and excluded based on clinical assessment and diagnostic tests. Recovery of Left Ventricular Dysfunction Within a Short Time Frame: The characteristic feature of TTCM is the transient nature of left ventricular dysfunction, with recovery typically occurring within weeks to months.

Medicine classes, NEET PG, NEETSS, NExT, NExT Exam

MULTIFOCAL ATRIAL TACHYCARDIA

#NEETPG #NEETSS #USMLE 2 min read Multifocal Atrial Tachycardia: A Diagnostic and Therapeutic Challenge Multifocal atrial tachycardia (MAT) presents a unique challenge for clinicians. Its variable presentation, non-specific symptoms, and potential for mimicking other arrhythmias necessitate a high index of suspicion and a nuanced approach to diagnosis and management. Clinical Presentation: While some patients with MAT may be asymptomatic, common presentations include: Palpitations Dyspnea Lightheadedness Fatigue The hallmark ECG finding in MAT is multiple P wave morphologies preceding each QRS complex, often with a short P-R interval. However, differentiating MAT from sinus tachycardia with varying P wave morphology or atrial flutter with conduction block requires careful analysis. Unveiling the Underlying Cause: Identifying the underlying condition driving MAT is crucial for optimal management. Here are some key areas to consider: Pulmonary Disease: Chronic obstructive pulmonary disease (COPD), acute respiratory failure, and pulmonary embolism can all trigger MAT. Cardiac Insults: Myocarditis, pericarditis, and coronary artery disease can create a substrate for MAT. Electrolyte Imbalances: Derangements in potassium, magnesium, or calcium can disrupt electrical conduction. Other: Stimulant use, upper GI bleed, and even thyrotoxicosis can be associated with MAT.   Therapeutic Strategies: Treatment for MAT revolves around addressing the underlying cause: Pulmonary Optimization: Managing COPD, treating respiratory failure, and anticoagulation for pulmonary embolism are crucial. Electrolyte Correction: Restoring electrolyte balance is essential for normal cardiac conduction. Medications: Calcium channel blockers, beta-blockers, or amiodarone can help control heart rate and rhythm. Catheter Ablation: When medications fail or the arrhythmia is highly symptomatic, catheter ablation targeting the ectopic foci in the atria can be curative.

Scroll to Top